Detalhe da pesquisa
1.
Perioperative Nivolumab in Resectable Lung Cancer.
N Engl J Med
; 390(19): 1756-1769, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38749033
2.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
N Engl J Med
; 386(21): 1973-1985, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403841
3.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Future Oncol
; 19(8): 549-557, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815433
4.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(2): 198-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476593
5.
Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy.
J Cell Mol Med
; 2021 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132464
6.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658845
7.
Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours.
Medicina (Kaunas)
; 57(8)2021 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34441012
8.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(25): 2415-2426, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636851
9.
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Br J Cancer
; 117(6): 757-766, 2017 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28772281
10.
Biomarkers for the early detection of relapses in metastatic colorectal cancers.
J BUON
; 22(3): 658-666, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28730771
11.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Lancet Oncol
; 16(5): 499-508, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25877855
12.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24933332
13.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(1): 59-68, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24331154
14.
MicroRNAs expression profile in chemotherapy-induced cardiotoxicity in NSCLC using a co-culture model.
Biomol Biomed
; 24(1): 125-137, 2024 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622179
15.
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
J Immunother Cancer
; 12(2)2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38346853
16.
Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective.
Cancers (Basel)
; 15(22)2023 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001653
17.
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
J Clin Oncol
; 41(6): 1200-1212, 2023 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36223558
18.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Eur J Cancer
; 183: 174-187, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871487
19.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Lancet Respir Med
; 11(1): 74-86, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36252599
20.
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
J Immunother Cancer
; 11(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725084